Amendment Statement of Principles 
concerning 
SARCOIDOSIS 
(Reasonable Hypothesis) 
(No. 13 of 2019)

The Repatriation Medical Authority determines the following Amendment Statement of Principles under subsections 196B(2) and (8) of the Veterans’ Entitlements Act 1986.

Dated 21 December 2018

The Common Seal of the Repatriation Medical Authority was affixed to this instrument at the direction of:

Professor Nicholas Saunders AO 
Chairperson
1 Name

This is the Amendment Statement of Principles concerning sarcoidosis (Reasonable Hypothesis) (No. 13 of 2019).

2 Commencement

This instrument commences on 28 January 2019.

3 Authority

This instrument is made under subsections 196B(2) and (8) of the Veterans' Entitlements Act 1986.

4 Amendment

The Statement of Principles concerning sarcoidosis (Reasonable Hypothesis) (No. 59 of 2016) (Federal Register of Legislation No. F2016L01144) is amended in the following manner:

<table>
<thead>
<tr>
<th>Section</th>
<th>Amendment</th>
</tr>
</thead>
</table>
| 9(1)    | Replace the existing factor in subsection 9(1) with the following:  
being treated with a drug from a class of drugs from the specified list of drugs within the five years before the clinical onset of sarcoidosis;  
Note: specified list of drugs is defined in the Schedule 1 - Dictionary. |
| 9(1a)   | Insert the following factor in subsection 9(1a):  
having immunotherapy for cancer or targeted therapy for cancer within the five years before the clinical onset of sarcoidosis;  
Note: immunotherapy for cancer and targeted therapy for cancer are defined in the Schedule 1 - Dictionary. |
| 9(3a)   | Insert the following factor in subsection 9(3a):  
having a malignant neoplasm in the ten years before the clinical onset of sarcoidosis; |
| 9(6)    | Replace the existing factor in subsection 9(6) with the following:  
being treated with a drug from a class of drugs from the specified list of drugs within the five years before the clinical worsening of sarcoidosis;  
Note: specified list of drugs is defined in the Schedule 1 - Dictionary. |
9(6a)  *Insert the following factor in subsection 9(6a):*  
having immunotherapy for cancer or targeted therapy for cancer within the five years before the clinical worsening of sarcoidosis;  
*Note:* **immunotherapy for cancer** and **targeted therapy for cancer** are defined in the Schedule 1 - Dictionary.

9(8a)  *Insert the following factor in subsection 9(8a):*  
having a malignant neoplasm in the ten years before the clinical worsening of sarcoidosis;

Schedule 1 – Dictionary  *Insert the following definition of "immunotherapy for cancer" in alphabetical order:*  
**immunotherapy for cancer** means the use of drugs to stimulate a person's own immune system to recognise and destroy cancer cells more effectively.

Schedule 1 – Dictionary  *Insert the following definition of "specified list of drugs" in alphabetical order:*  
**specified list of drugs** means:  
(a) BRAF/MEK inhibitors, including, but not limited to, vemurafenib, dabrafenib and trametinib;  
(b) immune checkpoint inhibitors, including, but not limited to, ipilimumab, pembrolizumab and nivolumab;  
(c) interferons; or  
(d) vaccines used to treat cancer.

Schedule 1 – Dictionary  *Insert the following definition of "targeted therapy for cancer" in alphabetical order:*  
**targeted therapy for cancer** means the use of drugs that block the growth and spread of cancer by interfering with specific molecules that are involved in the growth, progression or spread of cancer.